Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C6H8O6.C4H6N4O3 |
| Molecular Weight | 334.2396 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)NC1NC(=O)NC1=O.OC[C@H](O)[C@H]2OC(=O)C(O)=C2O
InChI
InChIKey=BMZVXYKKNCVBBF-RXSVEWSESA-N
InChI=1S/C6H8O6.C4H6N4O3/c7-1-2(8)5-3(9)4(10)6(11)12-5;5-3(10)6-1-2(9)8-4(11)7-1/h2,5,7-10H,1H2;1H,(H3,5,6,10)(H2,7,8,9,11)/t2-,5+;/m0./s1
| Molecular Formula | C4H6N4O3 |
| Molecular Weight | 158.1154 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | C6H8O6 |
| Molecular Weight | 176.1241 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfCurator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
Sources: http://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdf
Curator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
The aluminum salt of Allantoin, Alcloxa combines the astringent and anti-microbial properties of aluminum with the anti-irritant, soothing and healing properties of Allantoin. Alcloxa is particularly suited for use in anti-perspirants, acne treatments and foot care products. Alcloxa is a compound that combine the properties of aluminum salts with the properties of allantion. The allantion component ehhances the action of the aluminum salts and serves to overcome irritations experienced by many individuals who may be sensitive to the use of aluminum alts. The aluminum component reduces sweat by causing the sweat gland ducts swell. Alcloxa also add to the antiperspirant properties the deodorant effect because of its bacteriostatic action. It showed bacteriostatic properties at concentrations of 0.2% particularly against Gram bectaria (B. subtilis, S. aureus, P. vulgaris, Pityrosporum ovale). This is ascribable to two different mechanisms: first bacterial growth is retarded due to a decrease in the amount of water present, second aluminum salt have itself an antimicrobial action. In baby products is indicated for its healing reparative action, in the treatment of diaper rash. Also is approved in haemorrhoidal product for its soothing and keratolytic action. In oral care products Alcloxa is useful for its astringent antibacterial properties. It is very indicated in formulations for sensitive teeth, periodontal and gum diseases (like gingivitis, irritable and bleeding gums). Use levels: 0.1-1%. − In antiacne products the slightly astringent effect promotes healing of pustules and acne lesions. It reduces the extension of infected skin eruptions, healing them and developing a soothing action. May be used alone or also in combinations with other antimicrobial agents in order to fight acne more effectively. Use levels: 0.5-2.0%.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | BODYGLIDE FOR HER Approved Usehelps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns. Launch Date2009 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia. | 2015-12-01 |
|
| [Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions]. | 1994-03 |
|
| [The effect of aldioxa on the formation of gastritis induced with sodium hydroxide]. | 1990-11 |
|
| [Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats]. | 1989-11 |
|
| [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity]. | 1962-07-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:42 GMT 2025
by
admin
on
Mon Mar 31 18:00:42 GMT 2025
|
| Record UNII |
76WX3J5GER
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
67732897
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
PRIMARY | |||
|
127941-88-2
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
76WX3J5GER
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
PRIMARY | |||
|
76WX3J5GER
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
PRIMARY | |||
|
DTXSID90972924
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
PRIMARY | |||
|
2559842
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
PRIMARY | |||
|
57448-83-6
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
PRIMARY | |||
|
260-739-1
Created by
admin on Mon Mar 31 18:00:42 GMT 2025 , Edited by admin on Mon Mar 31 18:00:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |